If your dermatologist is recommending a Janus kinase (JAK) inhibitor to treat your atopic dermatitis (AD), the most common form of eczema, you may have questions: How does it compare with other options? How quickly will it ease my itching? And should I be worried about its safety and side effects?
JAK inhibitors are medications that block signals in the immune system that cause inflammation. They’re being used to treat dermatological conditions, including alopecia areata and vitiligo – and in people with AD, these medications can relieve itching while clearing skin.
JAK inhibitors can be an effective treatment option, but if you’re only familiar with medications like steroids and biologics, they may feel like unknown territory. Here’s a look at common misconceptions and important facts about JAK inhibitors to help you better understand their benefits and risks.
1. Misconception: JAK Inhibitors Are a Type of Biologic
Oral JAK inhibitors and biologics are both systemic treatments for AD, or treatments that work throughout the whole body, but they each work differently.
Advertisement
Advertisement
“People often confuse JAK inhibitors and biologics … they have the same desired outcome of clearance of skin, but they [use] different mechanisms of action,” says Dawn Davis, MD, a professor of dermatology and pediatrics at Mayo Clinic in Rochester, Minnesota, and a cochair of the American Academy of Dermatology guidelines committee for AD.
JAK inhibitors block inflammation within cells, while biologics for AD block inflammation signaling between cells.
But there are differences that help with decision-making on which to choose, too. “We have to think about practical things, such as monitoring requirements, whether it’s available in a pill or a shot and how palatable those options are, and insurance availability because oftentimes clinicians and patients are restricted based on insurance coverage,” Dr. Davis says.
Aside from the difference in how they work, each type of medication is administered differently: JAK inhibitors that work systemically are pills you take by mouth, while biologics are given as injections into the fat under your skin. (There are also topical JAK inhibitors, but those are typically used in mild to moderate AD.)
2. Fact: JAK Inhibitors Can Relieve Itching Quickly
A key benefit of JAK inhibitors is how quickly people report relief from itching.
Advertisement
Advertisement
A research review found that the oral JAK inhibitors abrocitinib (Cibinqo) and upadacitinib (Rinvoq) can ease itching within one to three days. It’s one of the remarkable things about JAK inhibitors, says Peter Lio, MD, a clinical assistant professor of dermatology and pediatrics at Northwestern University’s Feinberg School of Medicine in Chicago.
“Some patients notice meaningful improvement within just a few days, which can be life-changing for someone who has been suffering with relentless itching and poor sleep,” Dr. Lio says.
3. Misconception: JAK Inhibitors Are Only for the Most Severe Cases of Atopic Dermatitis
Because oral JAK inhibitors require extra legwork with screening and monitoring, including infection testing and blood work, they may seem like an option saved only for the most severe cases of AD. Abrocitinib, for example, is approved for people ages 12 and older with moderate to severe AD that hasn’t been managed well with other systemic treatments, including biologics, or when those treatments aren’t a good idea.
But that doesn’t mean your AD has to be severe to qualify, says Steven Daveluy, MD, a professor and the program director of the dermatology residency program at Wayne State University’s School of Medicine in Detroit, where he specializes in treating patients with skin conditions like psoriasis and eczema.
Advertisement
Advertisement
“They’re not typically the first treatment we reach for, but that doesn’t mean they’re only an option for the most severe cases,” Dr. Daveluy says. “While the most obvious candidate is someone with eczema affecting a large portion of their skin, it’s really important that we also consider the impact that the disease is having on the patient.”
He says dermatologists also consider whether AD affects areas such as the hands, feet, face, or genitals, where even small patches can have a big impact on daily life. They also consider how itching, burning, pain, and disrupted sleep affect your quality of life.
4. Fact: Screening and Follow-Up Are Important With Oral JAK Inhibitors
Don’t expect your dermatologist to simply write a prescription and send you to the pharmacy. Before prescribing an oral JAK inhibitor, your dermatologist will review your medical history, medications, and vaccinations.
Screening also includes checking for a range of conditions, including infections, plus blood tests to assess blood cell counts, liver and kidney function, and cholesterol levels. Your doctor will also ask about pregnancy plans, birth control use, and whether you’re breastfeeding before starting treatment.
Advertisement
Advertisement
“I tell my patients we’re checking to make sure you don’t have a tuberculosis or hepatitis infection that you don’t know about, since modifying your immune system could make an infection worse,” Daveluy says.
Guidelines call for repeating blood tests 4 to 12 weeks after starting, then every three to six months, depending on the medication.
“It’s about identifying potential problems early and helping patients benefit from treatment as safely as possible,” Daveluy says.
5. Misconception: The Black Box Warning Means Everyone Faces the Same Risk
The JAK inhibitors used for AD carry so-called black box warnings about serious infections, cancer, major cardiovascular events, blood clots, and death. “This is probably the biggest source of confusion and anxiety surrounding JAK inhibitors,” Lio says.
Advertisement
Advertisement
Much of the concern about cardiovascular events and cancer came from a study of oral tofacitinib (Xeljanz) in people with rheumatoid arthritis (RA) who were at least 50 years old and had at least one cardiovascular risk factor. Its findings led to expanded warnings for other JAK inhibitors, Lio says.
But people with RA may have a different risk profile from people with AD, Davis says. The findings don’t establish the individual risk for each person with AD.
Your personal and family medical history matter. Discuss your age and any history of infections, cardiovascular disease, cancer, or blood clots with your dermatologist to determine whether an oral JAK inhibitor is right for you, Daveluy says.
“If you have a family history or a personal history of [cancer], you may want to consult an oncologist before starting a JAK inhibitor or redirect your therapy to a different systemic option like a biologic,” Davis says.
6. Fact: Clearer Skin Doesn’t Mean Your Atopic Dermatitis Is Cured
You may see clearer skin within weeks, but that doesn’t mean you should stop treatment on your own. In one trial, about 44 percent of adults taking upadacitinib had a 75 percent improvement in the extent and severity of their AD after just two weeks. But another study found that after people stopped taking the medication, itching worsened within five days and any skin clearance response was gone within a month.
Advertisement
Advertisement
Researchers are working on understanding the distinction between disease control and true remission, Lio says. Ideally, it would look like reducing the intensity of treatment while still maintaining skin improvements. “We don’t yet have definitive evidence that this is happening … but it is an important direction for research and something I’m genuinely excited about,” Lio says.
For now, you should ask your dermatologist what maintenance should look like before adjusting your treatment plan. “For patients today, the practical message is that we shouldn’t stop treatment simply because the skin looks better,” Lio says.
The Takeaway
-
Oral JAK inhibitors work differently from biologics, offering another treatment option for people whose moderate to severe atopic dermatitis isn’t adequately controlled with other systemic medicines.
-
Screening, monitoring, and discussing your personal and family medical history with your dermatologist are important when you take JAK inhibitors, as black box warnings should be considered alongside your individual risks.
-
Itching may ease within days and skin may improve over weeks, but discuss a plan for maintenance with your dermatologist before discontinuing treatment, because symptoms can return after stopping.
EDITORIAL SOURCES
Everyday Health follows strict sourcing guidelines to ensure the accuracy of its content, outlined in our editorial policy. We use only trustworthy sources, including peer-reviewed studies, board-certified medical experts, patients with lived experience, and information from top institutions.
Advertisement
Advertisement
Resources
-
Kamata M et al. Optimal Use of Jak Inhibitors and Biologics for Atopic Dermatitis on the Basis of the Current Evidence. JID Innovations. May 2023.
-
Haag C et al. A Practical Guide to Using Oral Janus Kinase Inhibitors for Atopic Dermatitis from the International Eczema Council. British Journal of Dermatology. January 2025.
-
FDA Requires Warnings About Increased Risk of Serious Heart-Related Events, Cancer, Blood Clots, and Death for JAK Inhibitors That Treat Certain Chronic Inflammatory Conditions. U.S. Food & Drug Administration. December 7, 2021.
-
Blauvelt A et al. Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial. JAMA Dermatology. August 4, 2021.
-
Patel JD et al. Toward a Multidimensional Framework for Defining Remission in Atopic Dermatitis. Dermatitis. February 6, 2026.
Meet Our Experts
See Our Editorial Policy Meet Our Health Expert Network

Jacquelyn Dosal
Jacquelyn Dosal, MD
Medical Reviewer
Castle Connolly Top Doctor
Advertisement
Advertisement
Jacquelyn Dosal, MD, is a board-certified dermatologist practicing at The Dermatology House in Park City, Utah. Her areas of expertise include acne, rosacea, integrative treatments…
See full bio

carmen-chai-bio
Carmen Chai-Oakley
Author
Carmen Chai-Oakley is a Canadian journalist and award-winning health reporter. Her interests include emerging medical research, exercise, nutrition, mental health, and maternal and…
See full bio
See Our Editorial Policy Meet Our Health Expert Network




